Johnson & Johnson (NYSE:JNJ) shares rose today after the healthcare conglomerate reported Wall-Street-beating 3rd-quarter results, buoyed by its pharmaceuticals division.
Pharmaceutical
Diabetes: FDA warns 15 cos. on false labeling
The FDA this week warned consumers about a slew of companies making unverified and potentially dangerous claims about products marketed to patients with diabetes.
No less than 15 companies were accused of making unapproved claims and the FDA is "taking action to remove from the market illegal products," according to the notice.
Covidien puts a bow on pharma spinout, Wall Street backs off
Covidien’s Mallinckrodt pharma spinout slated to close this month | Wall Street Beat
Covidien (NYSE:COV) said it expects to close its spinout of the Mallinckrodt pharmaceuticals business by the end of this month, with a distribution of shares in the new company.
Mansfield, Mass.-based Covidien said it will issue 1 single share of Mallinckrodt stock for 8 shares of COV stock to interested investors, will all distributions scheduled for completion by June 28.
Covidien restates Q2 financials ahead of pharma spinout | Wall Street Beat
Covidien (NYSE:COV) re-stated its financial results for the fiscal 3rd quarter ended March 29, in anticipation of the planned spinout of its Mallinckrodt pharmaceuticals business next month.
Covidien said the new numbers reflect the pharma unit as a discontinued operation, with COV shareholders slated to receive a tax-free distribution, according to a regulatory filing.
Optimizing electronic medication administration records
In June, BIDMC goes live with Electronic Medication Records (EMAR) on one ward to be followed
by 3 other wards, ensuring we meet our 10% Meaningful Use Stage 2 target by the reporting period October 1-December 31, 2013.
We built a web-based, mobile friendly EMAR system that includes many visual cues and seamless integration (not interfacing) with all our existing clinical information systems.
Meet the ‘New Covidien’
Medical device tax cut about 4% from Q2 earnings growth, Becton Dickinson reports
Healthcare giant Becton Dickinson & Co. (NYSE:BDX) posted some ups and downs for its 2nd quarter of 2013, exceeding analysts’ expectations on earnings but taking some hits with lowered medical device sales and a nearly 4% cut in earnings growth due to the medical device tax.
Medtech sales reps out-earn pharma peers, survey says | MassDevice.com On Call
MASSDEVICE ON CALL — Medical device sales representatives earned more on average than their peers in any other healthcare segment, including healthcare IT, according to a 2012 survey by MedReps.com.
Although base salaries in the pharmaceutical, biotech/biopharma and health IT/software segments were higher, when combined with commissions and bonuses medtech sales reps earned top dollar at about $155,000 per year.